These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 15094233

  • 1. Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments.
    Hong SP, Kim NK, Hwang SG, Chung HJ, Kim S, Han JH, Kim HT, Rim KS, Kang MS, Yoo W, Kim SO.
    J Hepatol; 2004 May; 40(5):837-44. PubMed ID: 15094233
    [Abstract] [Full Text] [Related]

  • 2. Comparison of mass spectrometric analysis and TRUGENE HBV genotyping for monitoring lamivudine resistance in chronic hepatitis B patients.
    Woo HY, Park H, Kim BI, Jeon WK, Cho YK, Kim YJ.
    Antivir Ther; 2007 May; 12(1):7-13. PubMed ID: 17503742
    [Abstract] [Full Text] [Related]

  • 3. Predominance of hepatitis B virus YMDD mutants is prognostic of viral DNA breakthrough.
    Lee CH, Kim SO, Byun KS, Moon MS, Kim EO, Yeon JE, Yoo W, Hong SP.
    Gastroenterology; 2006 Apr; 130(4):1144-52. PubMed ID: 16618409
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of methods for monitoring drug resistance in chronic hepatitis B patients during lamivudine therapy based on mass spectrometry and reverse hybridization.
    Kim HS, Han KH, Ahn SH, Kim EO, Chang HY, Moon MS, Chung HJ, Yoo W, Kim SO, Hong SP.
    Antivir Ther; 2005 Apr; 10(3):441-9. PubMed ID: 15918335
    [Abstract] [Full Text] [Related]

  • 5. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
    Enomoto M, Tamori A, Kohmoto MT, Morikawa H, Habu D, Sakaguchi H, Takeda T, Seki S, Kawada N, Shiomi S, Nishiguchi S.
    J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
    [Abstract] [Full Text] [Related]

  • 6. Quantitative subtyping of hepatitis B virus reveals complex dynamics of YMDD motif mutants development during long-term lamivudine therapy.
    Ding C, Wong VW, Chow KC, Chan HY, Hui AY, Wong GL, Lo YM, Sung JJ, Chan HL.
    Antivir Ther; 2006 Nov; 11(8):1041-9. PubMed ID: 17302374
    [Abstract] [Full Text] [Related]

  • 7. [A real-time PCR assay for the quantification of hepatitis B virus DNA and concurrent detection of YMDD motif mutations].
    Ağca H, Sayıner AA, Sengönül A, Simşek I, Akarsu M.
    Mikrobiyol Bul; 2011 Oct; 45(4):664-76. PubMed ID: 22090297
    [Abstract] [Full Text] [Related]

  • 8. Hepatitis B virus quantification and detection of YMDD mutants in a single reaction by real-time PCR and annealing curve analysis.
    Shih YH, Yeh SH, Chen PJ, Chou WP, Wang HY, Liu CJ, Lu SF, Chen DS.
    Antivir Ther; 2008 Oct; 13(4):469-80. PubMed ID: 18672526
    [Abstract] [Full Text] [Related]

  • 9. [Detection and analysis of the new kind of G743C and G743A point mutation of HBV P gene in hepatitis B virus infected patients resistant to lamivudine].
    Pan XP, Wo JE, Chen Z, Chen F, Liang WF, Liu KZ.
    Zhonghua Gan Zang Bing Za Zhi; 2003 Oct; 11(10):616-8. PubMed ID: 14572341
    [Abstract] [Full Text] [Related]

  • 10. Identification of rare polymerase variants of hepatitis B virus using a two-stage PCR with peptide nucleic acid clamping.
    Ohishi W, Shirakawa H, Kawakami Y, Kimura S, Kamiyasu M, Tazuma S, Nakanishi T, Chayama K.
    J Med Virol; 2004 Apr; 72(4):558-65. PubMed ID: 14981758
    [Abstract] [Full Text] [Related]

  • 11. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.
    Pan XP, Li LJ, Du WB, Li MW, Cao HC, Sheng JF.
    J Viral Hepat; 2007 Nov; 14(11):767-74. PubMed ID: 17927612
    [Abstract] [Full Text] [Related]

  • 12. [Types and emergence time of YMDD motif mutation in hepatitis B virus polymerase gene during lamivudine treatment].
    Liang WF, Yang DH, Shen YH, Xie YJ, Zhao NF.
    Zhonghua Gan Zang Bing Za Zhi; 2003 May; 11(5):302-4. PubMed ID: 12773248
    [Abstract] [Full Text] [Related]

  • 13. YMDD motif variants in inactive hepatitis B carriers detected by Inno-Lipa HBV DR assay.
    Akarsu M, Sengonul A, Tankurt E, Sayiner AA, Topalak O, Akpinar H, Abacioglu YH.
    J Gastroenterol Hepatol; 2006 Dec; 21(12):1783-8. PubMed ID: 17074014
    [Abstract] [Full Text] [Related]

  • 14. [Detection of YMDD mutations in hepatitis B virus DNA with the use of allele specific polymerase chain reaction].
    Pichkovskaia VA, Fevraleva IS, Ibragimova MM, Solov'eva TI, Drel' PE, Sudarikov AB.
    Mol Gen Mikrobiol Virusol; 2004 Dec; (1):27-9. PubMed ID: 15025001
    [Abstract] [Full Text] [Related]

  • 15. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection.
    Ono-Nita SK, Kato N, Shiratori Y, Masaki T, Lan KH, Carrilho FJ, Omata M.
    Hepatology; 1999 Mar; 29(3):939-45. PubMed ID: 10051501
    [Abstract] [Full Text] [Related]

  • 16. Dynamic changes of hepatitis B virus polymerase gene including YMDD motif in lamivudine-treated patients with chronic hepatitis B.
    Feng B, Wei L, Chen M, Wang L.
    Microbiol Res; 2008 Mar; 163(4):487-92. PubMed ID: 17317127
    [Abstract] [Full Text] [Related]

  • 17. Application of PCR-LDR-nucleic acid detection strip in detection of YMDD mutation in hepatitis B patients treated with lamivudine.
    Xu G, You Q, Pickerill S, Zhong H, Wang H, Shi J, Luo Y, You P, Kong H, Lu F, Hu L.
    J Med Virol; 2010 Jul; 82(7):1143-9. PubMed ID: 20513076
    [Abstract] [Full Text] [Related]

  • 18. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance.
    Moskovitz DN, Osiowy C, Giles E, Tomlinson G, Heathcote EJ.
    J Viral Hepat; 2005 Jul; 12(4):398-404. PubMed ID: 15985011
    [Abstract] [Full Text] [Related]

  • 19. PCR restriction fragment length polymorphism in detection of YMDD variants of viral polymerase in hepatitis B virus patients treated with lamivudine.
    Yang DH, Liang WF, Xie YJ, Zhao NF, Fan J.
    Hepatobiliary Pancreat Dis Int; 2002 May; 1(2):232-7. PubMed ID: 14612274
    [Abstract] [Full Text] [Related]

  • 20. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
    Paik YH, Han KH, Hong SP, Lee HW, Lee KS, Kim SO, Shin JE, Ahn SH, Chon CY, Moon YM.
    Antivir Ther; 2006 May; 11(4):447-55. PubMed ID: 16856618
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.